AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN) reported Phase III CROSSING trial results showing TEZSPIRE® (tezepelumab-ekko) achieved statistically significant improvements in eosinophilic esophagitis outcomes, with benefits maintained through week 52.
AstraZeneca (NASDAQ:AZN) has reportedly engaged in early-stage negotiations regarding a potential merger with Bristol Myers Squibb (NYSE:BMY).
AstraZeneca (NYSE:AZN) reported second-quarter core EPS of $2.63, up 21%, as oncology and rare-disease sales grew.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said ENHERTU significantly improved progression-free survival versus standard first-line treatment in the Phase III DESTINY-Lung04 lung cancer trial.
AstraZeneca has explored an acquisition of Bristol Myers Squibb, according to people familiar with the matter. It's unclear if discussions are ongoing or whether they will result in a transaction, the people cautioned. A representative for AstraZeneca declined to comment and Bristol Myers Squibb couldn't immediately be reached for comment on the talks. Bloomberg's Manuel Baigorri reports.
